Endogenic EnanDrost Drostanolone Enantate

What is drostanolone enanthate?

Drostanolone enanthate (chemically 2α-methyl-dihydrotestosterone enanthate) is a long-acting ester of drostanolone, a derivative of dihydrotestosterone (DHT). Structurally, the molecule is based on DHT, where a methyl group in the 2α position has been added to the A-ring — a seemingly small modification with two crucial consequences. It blocks breakdown via 3α-hydroxysteroid dehydrogenase in muscle tissue, which preserves the androgenic potential of the substance locally, while the molecule becomes completely resistant to aromatization to estrogen.

Drostanolone was developed in the 1950s and was introduced in the early 1960s under the trade name Drolban from Syntex, and later in Europe as Masteril and Permastril. The original indication was the palliative treatment of inoperable breast cancer in postmenopausal women, a use based on the molecule's antiestrogenic profile and its ability to compete with endogenous estrogens at the receptor level. The indication was gradually abandoned when tamoxifen and later aromatase inhibitors showed better tolerability.

The enanthate, with a heptanoic acid chain of seven carbons, gives the preparation a half-life of around 7–10 days and a very prolonged release profile from the depot at the injection site. The ratio of anabolic to androgenic activity is stated in the literature to be approximately 62:25 with testosterone as a reference of 100:100 — a relatively mild anabolic component with a distinct androgenic character.

How does drostanolone enanthate work?

At the cellular level, drostanolone binds to the androgen receptor (AR) with good affinity. The formed ligand-receptor complex is moved to the cell nucleus and controls the transcription of genes linked to protein synthesis, nitrogen balance and certain structural proteins in muscle and connective tissue.

What distinguishes drostanolone from classic anabolic steroids is related to the DHT basic structure and the 2α-methylation. The substance cannot be aromatized to estradiol because the aromatase enzyme lacks the ability to act on 5α-reduced steroids. Drostanolone itself also acts as a weak competitive inhibitor of aromatase and can block the conversion of endogenous testosterone to estrogen. The pharmacological basis for the original oncological use lies precisely here.

A third property concerns the binding to sex hormone-binding globulin (SHBG). Drostanolone has a high affinity for this transport protein, significantly higher than testosterone. In practice, the molecule displaces testosterone from SHBG and increases the fraction of free testosterone in the blood. The same DHT structure makes the substance insensitive to 5α-reductase — it is already in a reduced form — and is not exposed to further activation in the skin or prostate.

What can drostanolone enanthate potentially affect?

In the available pharmacological literature and in clinical data from the period when drostanolone was widely used, several physiological systems where the substance leaves its mark are found:

• Muscle tissue — activation of AR in skeletal muscle cells increases protein synthesis and improves nitrogen balance, albeit to a more moderate degree than with more potent anabolic compounds. The effect is characteristically "dry" because estrogenic water retention is missing.

• Estrogen metabolism — competitive aromatase inhibition and high SHBG affinity alter the ratio of circulating estrogenic and androgenic fractions, a phenomenon documented in pharmacokinetic studies in oncology patients.

• The hypothalamus-pituitary-gonadal axis (HPG) — like other exogenous androgens, drostanolone via negative feedback lowers the secretion of GnRH as well as LH and FSH, with consequent downregulation of endogenous testosterone production.

• Lipid Metabolism — DHT derivatives shift the lipid profile more markedly than aromatizing compounds, because the liver lacks the counterbalance that estrogen normally exerts on HDL synthesis.

Potential side effects of drostanolone enanthate

The side effect profile of drostanolone enanthate differs from other anabolic steroids on several points, mainly due to the DHT basic structure of the molecule and the lack of estrogen conversion. However, the absence of estrogenic side effects such as gynecomastia, water retention and edema does not mean that the substance is free of negative effects — on the contrary, a number of effects become more pronounced precisely because of the unchanged androgenic potential and the long release profile of the enantate.

• Androgenic effects — acne, seborrhea, oily skin, accelerated male pattern baldness in genetically predisposed individuals and increased sebum production, often more pronounced than with aromatizing androgens.

• Hormonal changes—prolonged suppression of the HPG axis with consequent hypogonadism after cessation of exposure, decreased levels of endogenous testosterone, LH, and FSH, and impaired spermatogenesis. Recovery can take months.

• Cardiovascular effects — unfavorable shift in the lipid profile with lowered HDL and elevated LDL, increased blood pressure and, in the long term, increased risk of left ventricular hypertrophy and endothelial dysfunction.

• Hepatological — relatively mild burden because the enantaster is administered parenterally and bypasses first-pass metabolism, but liver enzyme values may be shifted with prolonged exposure.

• Psychological — mood swings, irritability, increased aggression and sleep disturbances, with depression in the withdrawal phase.

• In women — pronounced risk of virilization symptoms: voice deepening, hirsutism, clitoral hypertrophy and menstrual disorders. Some changes are permanent even after exposure ends.

• Local — pain and infiltrates and risk of bacterial infections or sterile abscesses at the injection site.

The overall side effect picture of drostanolone enanthate — marked androgenic character, lipid impact and long-lasting HPG suppression — means that clinical use requires regular laboratory checks (lipid status, blood count, liver enzymes, hormone panel). The caution applies especially in women, where the virilization effects can be difficult to reverse.